PT  - JOURNAL ARTICLE
AU  - MARJAŃSKA, AGATA
AU  - DROGOSIEWICZ, MONIKA
AU  - DEMBOWSKA-BAGIŃSKA, BOŻENNA
AU  - PAWIŃSKA-WĄSIKOWSKA, KATARZYNA
AU  - BALWIERZ, WALENTYNA
AU  - BOBEFF, KATARZYNA
AU  - MŁYNARSKI, WOJCIECH
AU  - MIZIA-MALARZ, AGNIESZKA
AU  - RACIBORSKA, ANNA
AU  - WYSOCKI, MARIUSZ
AU  - STYCZYŃSKI, JAN
TI  - Nivolumab for the Treatment of Advanced Pediatric Malignancies
AID  - 10.21873/anticanres.14738
DP  - 2020 Dec 01
TA  - Anticancer Research
PG  - 7095--7100
VI  - 40
IP  - 12
4099  - http://ar.iiarjournals.org/content/40/12/7095.short
4100  - http://ar.iiarjournals.org/content/40/12/7095.full
SO  - Anticancer Res2020 Dec 01; 40
AB  - Background/Aim: Nivolumab is an immune checkpoint inhibitor with high antitumor activity in selected neoplasms. The aim of the study was to evaluate the efficacy and safety of nivolumab in pediatric patients with various types of highly malignant advanced tumors. Patients and Methods: Ten patients with a median age of 15.1 years were included in the study. The indications for treatment were: malignant skin melanoma (n=5), brain tumor (n=2), malignant melanoma of the brain (n=1), Hodgkin lymphoma (n=1) and soft tissue sarcoma (n=1). Results: Complete disease remission was observed in 4 patients. Overall survival at 24 months from diagnosis for the entire group was 0.36. Two patients receiving combination therapy of nivolumab and ipilimumab did not achieve a remission. Adverse events of immunotherapy were observed in 4/10 patients. Conclusion: Nivolumab is a promising option in pediatric advanced malignancies. Treatment with immunotherapy was relatively well tolerated, and emerging side-effects were manageable.